Timothy S. Fenske, MD, MS,

Timothy S. Fenske, MD, MS, professor of Medicine, the Medical College of Wisconsin, shares an initial report of the randomized, phase 3 ECOG-ACRIN EA4151 trial (NCT03267433), evaluating the use of autologous stem cell transplant in patients with mantle cell lymphoma with undetectable minimal residual disease following first complete remission. Fenske and colleagues shared these results in a presentation at the 

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


ASH Annual Meeting and Exposition

Timothy S. Fenske, MD, MS, shares outcomes from the phase 3 ECOG-ACRIN EA4151 trial of patients with mantle cell lymphoma after first MRD-negative CR.

Dr Fenske on ASCT Outcomes in MCL After First MRD-Negative CR